Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 224.00K | 384.30K | 200.10K | 192.30K | 209.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.00M | 940.40K | 496.90K | 534.70K | 632.90K |
| Operating Income | -1.00M | -940.40K | -496.90K | -534.70K | -632.90K |
| Income Before Tax | -983.00K | -805.10K | -481.60K | -476.00K | -527.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -983.00K | -805.10K | -481.60K | -476.00K | -527.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -983.00K | -805.10K | -481.60K | -476.00K | -527.00K |
| EBIT | -1.00M | -940.40K | -496.90K | -534.70K | -632.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 46.02M | 45.76M | 45.50M | 45.50M | 44.69M |
| Average Diluted Shares Outstanding | 46.02M | 45.76M | 45.50M | 45.50M | 44.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |